FDA accepts Merck application for expanded use of Recarbrio

The FDA has accepted for review Merck’s (NYSE:MRK) supplemental marketing application seeking approval to use combo antibiotic Recarbrio (imipenem, cilastatin and relebactam) to treat adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.

The agency’s action date is June 4.

The FDA approved Recarbrio in June 2019 for complicated urinary tract and complicated intra-abdominal bacterial infections.

https://seekingalpha.com/news/3537216-fda-accepts-merck-application-for-expanded-use-of-recarbrio